In 2023, Ireland leads global respiratory system medicine sales with a notable increase of 1.18%. Sweden and New Zealand follow closely, showing modest gains of 0.74% and 0.25% respectively. Luxembourg continues to climb with a 1.13% rise, whereas the United Kingdom and Chile experience significant declines of -2.09% and -6.3% respectively. Australia's market grows by 4.13%, contrasting with Croatia and Finland, which see decreases of -1.06% and -4.21% respectively.
Future trends to watch in the global respiratory system medicine market include potential growth in emerging markets and the development of advanced therapies. Monitoring these trends will be crucial for making informed strategic decisions in this evolving market.
Top countries in Respiratory System Medicine Sales by Country
| # | 10 Countries | Percent of Total Sales | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Ireland | 10.5 | 2023 | +5% | +1.18% | View data |
| 2 | 2 Sweden | 8.3 | 2023 | 0% | +0.74% | View data |
| 3 | 3 New Zealand | 8.2 | 2023 | -1.2% | +0.25% | View data |
| 4 | 4 Czech Republic | 7.8 | 2023 | +4% | 0% | View data |
| 5 | 5 Luxembourg | 7.3 | 2023 | -2.67% | +1.13% | View data |
| 6 | 6 United Kingdom | 7.2 | 2023 | -2.7% | -2.09% | View data |
| 7 | 7 Chile | 6.5 | 2023 | -22.62% | -6.3% | View data |
| 8 | 8 Australia | 6 | 2023 | -1.64% | +4.13% | View data |
| 9 | 9 Croatia | 5.5 | 2023 | +1.85% | -1.06% | View data |
| 10 | 10 Finland | 5 | 2023 | -1.96% | -4.21% | View data |
